SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-287960
Filing Date
2021-09-30
Accepted
2021-09-30 16:05:43
Documents
13
Period of Report
2021-09-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d237206d8k.htm   iXBRL 8-K 28561
2 EX-99.1 d237206dex991.htm EX-99.1 2077
  Complete submission text file 0001193125-21-287960.txt   155091

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lyel-20210929.xsd EX-101.SCH 2871
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20210929_lab.xml EX-101.LAB 18123
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20210929_pre.xml EX-101.PRE 11391
6 EXTRACTED XBRL INSTANCE DOCUMENT d237206d8k_htm.xml XML 3359
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 211295136
SIC: 2834 Pharmaceutical Preparations